IDH1 and central nervous system cancer: Mutations in the IDH1/2 have been identified in gliomas, and IDH-mutant low-grade gliomas (LGGs) may develop malignant transformation after further genetic alterations, such as Myc, PTEN, KRAS, PIK3CA, and MET, are acquired.